RU2017115719A - Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки - Google Patents
Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки Download PDFInfo
- Publication number
- RU2017115719A RU2017115719A RU2017115719A RU2017115719A RU2017115719A RU 2017115719 A RU2017115719 A RU 2017115719A RU 2017115719 A RU2017115719 A RU 2017115719A RU 2017115719 A RU2017115719 A RU 2017115719A RU 2017115719 A RU2017115719 A RU 2017115719A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- amino acid
- pharmaceutical composition
- antigen
- presenter
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 title 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 title 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 claims 6
- 230000036039 immunity Effects 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464476—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Пептид, содержащий 8 или более последовательных аминокислотных остатков одной из аминокислотных последовательностей SEQ ID NO: 1-15 и состоящий из 11 или менее аминокислотных остатков.
2. Пептид по п.1, где аминокислотная последовательность содержит 1 или более аминокислотных замен, вставок, делеций или добавлений, а пептид обладает иммуногенностью.
3. Пептид по п.2, где аминокислота в положении 2 аминокислотной последовательности заменена на тирозин, фенилаланин, метионин, триптофан, валин, лейцин или глутамин, и/или аминокислота на C-конце заменена на фенилаланин, лейцин, изолейцин, триптофан, метионин или валин.
4. Фармацевтическая композиция для лечения или профилактики рака, содержащая пептид по любому из пп.1-3.
5. Фармацевтическая композиция по п.4, где композиция находится в виде вакцины.
6. Фармацевтическая композиция по п.4 или 5, где пептид способен связываться с молекулами HLA одного или более типов.
7. Индуктор иммунитета, содержащий пептид по любому из пп.1-3.
8. Индуктор иммунитета по п.7, где индуктор способен индуцировать цитотоксическую T-клетку.
9. Индуктор иммунитета по п.7 или 8, где пептид способен связываться с молекулами HLA одного или более типов.
10. Способ получения антиген-презентирующей клетки, обладающей CTL-индуцирующей активностью, включающий в себя стадию приведения в контакт пептида по любому из пп.1-3 и антиген-презентирующей клетки in vitro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014206730 | 2014-10-07 | ||
| JP2014-206730 | 2014-10-07 | ||
| PCT/JP2015/078504 WO2016056596A1 (ja) | 2014-10-07 | 2015-10-07 | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017115719A3 RU2017115719A3 (ru) | 2018-11-14 |
| RU2017115719A true RU2017115719A (ru) | 2018-11-14 |
| RU2684911C2 RU2684911C2 (ru) | 2019-04-16 |
Family
ID=55653202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115719A RU2684911C2 (ru) | 2014-10-07 | 2015-10-07 | Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10537626B2 (ru) |
| EP (2) | EP3205661B1 (ru) |
| JP (1) | JP6423889B2 (ru) |
| CN (1) | CN107001418A (ru) |
| AU (2) | AU2015329070B2 (ru) |
| BR (1) | BR112017006969A2 (ru) |
| CA (2) | CA2963909C (ru) |
| DK (1) | DK3205661T3 (ru) |
| ES (1) | ES2882827T3 (ru) |
| RU (1) | RU2684911C2 (ru) |
| TW (1) | TWI687434B (ru) |
| WO (1) | WO2016056596A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963909C (en) | 2014-10-07 | 2021-06-15 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
| WO2016143816A1 (ja) | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| WO2016163489A1 (ja) | 2015-04-07 | 2016-10-13 | 日本電気株式会社 | 医薬 |
| ES2972560T3 (es) * | 2016-10-11 | 2024-06-13 | Nec Corp | Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3 |
| WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人ｔ細胞白血病の治療又は予防のための医薬組成物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196523A (en) | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
| JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤 |
| EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| EP1319023B8 (en) * | 2000-09-13 | 2009-07-15 | multimmune GmbH | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
| CN1555272A (zh) * | 2001-07-31 | 2004-12-15 | �ո��� | 调节免疫应答的组合物和方法 |
| JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
| US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US20090144209A1 (en) | 2004-07-07 | 2009-06-04 | Nec Corporation | Sequence prediction system |
| WO2006123155A2 (en) | 2005-05-19 | 2006-11-23 | Glaxosmithkline Biologicals S.A. | Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant |
| KR101304243B1 (ko) | 2005-08-09 | 2013-09-05 | 온코세라피 사이언스 가부시키가이샤 | ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약 |
| WO2007119515A1 (ja) * | 2006-03-28 | 2007-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原ペプチド |
| RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
| CN102850434B (zh) * | 2006-10-17 | 2016-04-13 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
| WO2008106491A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
| CN101801402B (zh) * | 2007-07-06 | 2013-08-28 | 乌得勒支大学控股有限公司 | 炎性疾病和自身免疫疾病的治疗和预防 |
| EP2195333A1 (en) * | 2007-09-12 | 2010-06-16 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
| KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| WO2011017162A2 (en) * | 2009-08-03 | 2011-02-10 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
| CN104136614B (zh) | 2009-10-06 | 2018-04-06 | 帕纳塞拉实验室有限责任公司 | Toll‑样受体和激动剂用于治疗癌症的用途 |
| MX2014009285A (es) * | 2012-02-07 | 2015-02-04 | Jolla Inst Allergy Immunolog | Alergenos del fleo de los prados y metodos y usos para la modulacion de respuesta inmune. |
| US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
| WO2013143026A1 (en) * | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
| TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| CN103897047B (zh) * | 2012-12-27 | 2016-01-20 | 中国科学院植物研究所 | 蛋白BhHSP70-1及其编码基因与应用 |
| CN105025884B (zh) | 2013-03-01 | 2019-08-20 | 阿斯泰克斯制药公司 | 药物组合 |
| CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
| CA2963909C (en) | 2014-10-07 | 2021-06-15 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
| WO2016143816A1 (ja) | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| WO2016163489A1 (ja) | 2015-04-07 | 2016-10-13 | 日本電気株式会社 | 医薬 |
-
2015
- 2015-10-07 CA CA2963909A patent/CA2963909C/en not_active Expired - Fee Related
- 2015-10-07 AU AU2015329070A patent/AU2015329070B2/en active Active
- 2015-10-07 BR BR112017006969A patent/BR112017006969A2/pt not_active IP Right Cessation
- 2015-10-07 CN CN201580054234.7A patent/CN107001418A/zh active Pending
- 2015-10-07 DK DK15849707.3T patent/DK3205661T3/da active
- 2015-10-07 EP EP15849707.3A patent/EP3205661B1/en active Active
- 2015-10-07 US US15/516,918 patent/US10537626B2/en active Active
- 2015-10-07 WO PCT/JP2015/078504 patent/WO2016056596A1/ja active Application Filing
- 2015-10-07 TW TW104133022A patent/TWI687434B/zh not_active IP Right Cessation
- 2015-10-07 JP JP2016553137A patent/JP6423889B2/ja active Active
- 2015-10-07 EP EP21174944.5A patent/EP3925968A3/en active Pending
- 2015-10-07 RU RU2017115719A patent/RU2684911C2/ru active
- 2015-10-07 CA CA3116265A patent/CA3116265A1/en not_active Abandoned
- 2015-10-07 ES ES15849707T patent/ES2882827T3/es active Active
-
2018
- 2018-12-06 AU AU2018274976A patent/AU2018274976B2/en active Active
-
2019
- 2019-12-16 US US16/715,758 patent/US11304997B2/en active Active
-
2022
- 2022-03-11 US US17/693,046 patent/US20220193213A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2882827T3 (es) | 2021-12-02 |
| AU2018274976B2 (en) | 2019-05-02 |
| RU2017115719A3 (ru) | 2018-11-14 |
| US20220193213A1 (en) | 2022-06-23 |
| US20180169199A1 (en) | 2018-06-21 |
| EP3205661A1 (en) | 2017-08-16 |
| EP3925968A3 (en) | 2022-03-02 |
| CA2963909A1 (en) | 2016-04-14 |
| EP3925968A2 (en) | 2021-12-22 |
| JP6423889B2 (ja) | 2018-11-14 |
| AU2015329070B2 (en) | 2018-11-22 |
| CN107001418A (zh) | 2017-08-01 |
| US20200121772A1 (en) | 2020-04-23 |
| AU2018274976A1 (en) | 2019-01-03 |
| US10537626B2 (en) | 2020-01-21 |
| WO2016056596A1 (ja) | 2016-04-14 |
| CA2963909C (en) | 2021-06-15 |
| TWI687434B (zh) | 2020-03-11 |
| CA3116265A1 (en) | 2016-04-14 |
| RU2684911C2 (ru) | 2019-04-16 |
| AU2015329070A1 (en) | 2017-04-27 |
| DK3205661T3 (da) | 2021-08-02 |
| JPWO2016056596A1 (ja) | 2017-08-17 |
| EP3205661B1 (en) | 2021-07-07 |
| BR112017006969A2 (pt) | 2017-12-19 |
| US11304997B2 (en) | 2022-04-19 |
| TW201619190A (zh) | 2016-06-01 |
| EP3205661A4 (en) | 2018-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115719A (ru) | Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки | |
| RU2017135038A (ru) | Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| EP4233898A3 (en) | Influenza mrna vaccines | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| EA202090751A3 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| MY170927A (en) | Influenza virus vaccines and uses thereof | |
| EP3363458A3 (en) | A peptide | |
| RU2010110567A (ru) | Пептид foxm1 и включающее его медицинское средство | |
| NZ628756A (en) | Immunogens for hiv vaccination | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| RU2016138365A (ru) | Pcsk9 вакцины | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| EA201892320A1 (ru) | Способ лечения или предупреждения остеоартрита | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2020109780A3 (en) | Polypeptide and uses thereof | |
| NZ742663A (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| RU2016145258A (ru) | Микроорганизм, обладающий улучшенным уровнем внутриклеточной энергии, и способ продуцирования l-аминокислоты с его помощью | |
| EA201792640A1 (ru) | Устойчивые к действию протеазы липидированные аналоги glp-1 | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| RU2017125261A (ru) | Способ и промежуточные соединения для получения прегабалина | |
| MX363464B (es) | Vacunas contra influenza h5. | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae |